Iqirvo PBC denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for iqirvo pbc are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Issues a "Not FDA-Approved" Denial for Iqirvo in PBC — and Why It May Be Incorrect

This denial category typically arises from one of three scenarios: (1) an administrative coding error in which the claim was submitted under the wrong diagnosis or indication code; (2) Aetna's review system has not yet updated to reflect Iqirvo's FDA approval status for PBC; or (3) the prescription is being written for an off-label use that falls outside the approved indication. If your prescriber is using Iqirvo for the FDA-approved PBC indication, this denial is likely factually incorrect and is directly appealable on that basis.

Iqirvo (elafibranor) holds FDA approval for primary biliary cholangitis. This is a matter of public record verifiable through the FDA's official drug database.

## Your Federal Appeal Rights

• ERISA §503: You have the right to a full-and-fair internal appeal. An incorrect factual premise — that the drug lacks FDA approval for your indication — is grounds for reversal at the internal level.
• ACA §2719 external review: If the internal appeal fails, an independent external reviewer can and should correct factual errors. The external-review window is generally four months from denial. Expedited review is available for urgent cases.
• State insurance department: A denial based on a false factual claim (drug not approved when it is) may constitute an improper claims practice — worth reporting to your state regulator.

## Concrete Appeal Steps

1. Pull the official FDA approval letter or drug label for Iqirvo from the FDA website and attach it to your appeal. 2. Confirm with your prescriber that the diagnosis code (ICD-10) on the prescription and claim matches the FDA-approved indication for PBC. 3. Request Aetna's Clinical Policy Bulletin for Iqirvo or elafibranor — review whether they are applying a restrictive internal definition that narrows the FDA indication. 4. Submit a short, direct internal appeal: attach the FDA label, state the diagnosis code, and ask Aetna to identify specifically which aspect of the FDA indication they believe is not met. 5. If denied internally, escalate to external review immediately.

## Documentation to Gather

• FDA prescribing label: Downloaded from FDA.gov — the most authoritative refutation of a "not approved" claim.
• Diagnosis documentation: Records from your hepatologist or gastroenterologist confirming your PBC diagnosis with specificity (serology, pathology, clinical criteria).
• Claim submission records: The original prior authorization request showing the diagnosis and indication codes used.
• Prescriber letter: Stating clearly that Iqirvo is being prescribed for the FDA-approved indication of PBC.

## Criteria-Mapping Structure

Because the core dispute is factual (approved vs. not approved), your mapping is simple:

| Aetna's Denial Claim | Counter-Evidence | |---|---| | Drug not FDA-approved for this use | FDA label approval date and indication statement | | [Any secondary criteria Aetna raises] | [Exact chart documentation] |

Keep the appeal focused and factual. Attach primary sources — the FDA label — rather than relying on assertions alone.